Invega Sustenna and Breastfeeding
The potential risks of receiving Invega Sustenna (paliperidone palmitate) while breastfeeding are currently unknown. However, the active ingredient in the drug has been shown to pass through breast milk. Due to the potential problems that may occur in a nursing infant, the manufacturer of the drug recommends that women not receive Invega Sustenna while nursing.
Can Breastfeeding Women Receive Invega Sustenna?Invega® Sustenna® (paliperidone palmitate) is a medication used to treat people with schizophrenia. This medication passes through breast milk in humans. The manufacturer of the drug recommends that women not receive Invega Sustenna while breastfeeding.
More Information on Invega Sustenna and BreastfeedingInvega Sustenna has not been studied in women who were breastfeeding. However, paliperidone (the active ingredient in Invega Sustenna) was shown to pass through breast milk in animal studies.
Paliperidone is a metabolite of risperidone (Risperdal®) -- this means that risperidone is changed into paliperidone in the body. Risperidone has been studied in breastfeeding women. Clinical studies have investigated how much risperidone and paliperidone were found in the breast milk of women who took risperidone. In the studies, paliperidone was found in breast milk in very small amounts; in addition, minimal to no drug was detectable in the nursing infants.
There is currently no information on the amount of paliperidone that might be found in breast milk after a women is given Invega Sustenna, which is a long-acting medication. In addition, the effects, if any, of the medicine on a nursing infant are unknown. If your healthcare provider recommends using this drug while breastfeeding, be sure to watch for any side effects of Invega Sustenna in your child.